These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 28854272

  • 1. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.
    PLoS One; 2017; 12(8):e0182885. PubMed ID: 28854272
    [Abstract] [Full Text] [Related]

  • 2. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 3. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
    Lee CK, Kim S, Lee JS, Lee JE, Kim SM, Yang IS, Kim HR, Lee JH, Kim S, Cho BC.
    Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ.
    Int J Cancer; 2019 Jun 01; 144(11):2887-2896. PubMed ID: 30485437
    [Abstract] [Full Text] [Related]

  • 5. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
    Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S.
    Clin Cancer Res; 2008 Nov 01; 14(21):7060-7. PubMed ID: 18981003
    [Abstract] [Full Text] [Related]

  • 6. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
    Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F.
    Clin Lung Cancer; 2014 Nov 01; 15(6):411-417.e4. PubMed ID: 25242668
    [Abstract] [Full Text] [Related]

  • 7. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
    Santoni-Rugiu E, Grauslund M, Melchior LC, Costa JC, Sørensen JB, Urbanska EM.
    Lung Cancer; 2017 Nov 01; 113():14-17. PubMed ID: 29110841
    [Abstract] [Full Text] [Related]

  • 8. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Inaba Y, Hida T, Yatabe Y.
    Clin Lung Cancer; 2017 Nov 01; 18(6):698-705.e2. PubMed ID: 28596108
    [Abstract] [Full Text] [Related]

  • 9. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
    Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K.
    Lung Cancer; 2013 Nov 01; 82(2):294-8. PubMed ID: 24035188
    [Abstract] [Full Text] [Related]

  • 10. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
    Ou SH, Soo RA.
    Drug Des Devel Ther; 2015 Nov 01; 9():5641-53. PubMed ID: 26508839
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 12. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q, Quan Q, Ding L, Hong X, Zhou N, Liang Y, Wu H.
    Oncotarget; 2015 Sep 22; 6(28):24904-11. PubMed ID: 26172562
    [Abstract] [Full Text] [Related]

  • 13. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS, Kwon JW, Shin S, Kim HS, Kim H.
    J Clin Pharm Ther; 2015 Dec 22; 40(6):661-71. PubMed ID: 26573867
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y, Wang Y, James M, Jeong JH, You M.
    Mol Carcinog; 2016 May 22; 55(5):991-1001. PubMed ID: 26052929
    [Abstract] [Full Text] [Related]

  • 15. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 22; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 16. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M, Stordal B.
    Drug Resist Updat; 2011 Jun 22; 14(3):177-90. PubMed ID: 21435938
    [Abstract] [Full Text] [Related]

  • 17. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.
    Lung Cancer; 2014 Jul 22; 85(1):19-24. PubMed ID: 24768581
    [Abstract] [Full Text] [Related]

  • 18. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M, Afatinib Compassionate Use Consortium (ACUC).
    Oncologist; 2015 Oct 22; 20(10):1167-74. PubMed ID: 26354527
    [Abstract] [Full Text] [Related]

  • 19. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ, Bazhenova LA, Braiteh FS, Nikolinakos PG, Gowen K, Cervantes CM, Chmielecki J, Greenbowe JR, Ross JS, Stephens PJ, Miller VA, Ali SM, Ou SH.
    Lung Cancer; 2015 Sep 22; 89(3):357-9. PubMed ID: 26187428
    [Abstract] [Full Text] [Related]

  • 20. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M, Okamoto I, Nakagawa K.
    Lung Cancer; 2015 Apr 22; 88(1):74-9. PubMed ID: 25704957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.